RAC Gamma Serine/Threonine Protein Kinase Market Size, Share, Analysis, Industry Report and Forecast 2022-2028

The global RAC gamma serine/threonine-protein kinase market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). AKT3 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2, and AKT3) that regulate a variety of functions including metabolism, cell survival, growth, and angiogenesis. This is accomplished by phosphorylating a variety of downstream substrates with serine and/or threonine. So far, over 100 substrate candidates have been reported, however, none of them have been shown to be isoform-specific. AKT3 is the AKT isoform that has received the least amount of research. It is essential for the viability of malignant glioma cells and plays a critical function in brain development. The expression of the phosphorylated form of Bcl-2 agonist of cell death (BAD) is reduced by RNA interference, resulting in caspase-dependent apoptosis induction.

To Request a Sample of our Report on RAC Gamma Serine/Threonine Protein Kinase Market: https://www.omrglobal.com/request-sample/rac-gamma-serine-threonine-protein-kinase-market

Additionally, based on the application the RAC gamma serine-threonine protein kinase market is segmented into breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, and others. The breast cancer segment is expected to hold a lucrative share in the market during the forecast period. Breast cancer is the second most common cancer, globally. According to the WHO, breast cancer held 11.7% of new cases in all types of cancers in 2020. Breast cancer is the most common cancer in women both in developed and emerging economies. Emerging economies have the highest number of breast cancer incidences due to a sedentary lifestyle and lack of awareness regarding the disease. In Asia, 10,26,171 new cases of breast cancer were reported in 2020 with approximately 346,009 mortalities. The high incidence related to breast cancer in women across the globe is primarily driving the growth of the segment.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck & Co., Inc., AstraZeneca Plc, and Novartis International AG among others.

(Get 15% Discount on Buying this Report)

A full Report of RAC Gamma Serine/Threonine Protein Kinase Market is Available @ https://www.omrglobal.com/industry-reports/rac-gamma-serine-threonine-protein-kinase-market

Global RAC Gamma Serine/Threonine Protein Kinase Market Report by Segment

By Type

· MK-2206

· JRP-890

· ISC-4

· AZD-5363.

By Application

· Breast Cancer

· Endometrial Cancer

· Non-Small Cell Lung Cancer

· Ovarian Cancer

· Cervical Cancer

· Others

Global RAC Gamma Serine/Threonine Protein Kinase Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.